Navigation Links
WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
Date:6/28/2009

SHANGHAI, June 29 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) announced today that it had been selected by China's Ministry of Commerce to the list of Top Ten Leading Outsourcing Enterprises in China. The list was announced at the Second Annual China International Service Outsourcing Cooperation Conference, held in Nanjing on June 23 and 24, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

According to the ministry, revenue generated by Chinese outsourcing companies in 2008 grew 34% year over year to $1.5 billion. The top ten companies produced almost one third of that revenue. Those companies represented the healthcare, service and manufacture, government, education and finance sectors. WuXi PharmaTech was the only winner in healthcare.

"We are honored to receive this recognition by the Ministry of Commerce," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "Outsourcing benefits not only China by tapping the skills and talents of our country's productive workforce, but also benefits countries around the world with high-quality, cost-effective products and services provided by outsourcing service companies. We are grateful to the Ministry of Commerce for its generous support of WuXi and the outsourcing industry in general. With continued support, we will continue to develop both capabilities and capacity to better serve the world's leading life science companies."

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, we provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners to improve the success of research and shorten the time of development cost effectively in discovering and developing drugs and medical devices.

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com

     Web:http://www.wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
2. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
3. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
4. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
5. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
6. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
7. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
8. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
9. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
10. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
11. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Meister ... mind, the fresh look and added functionality give the agricultural world a taste ... a dynamic shift in agriculture – from precision farming via satellites and Unmanned ...
(Date:4/29/2016)... Italy (PRWEB) , ... April 30, 2016 , ... The ... extraordinary textile design, the bioLogic team explored how bacterial properties can be applied to ... of using Natto bacteria, which move in response to humidity change. The team harvested ...
(Date:4/29/2016)... , April 29, 2016 ... Transparency Market Research "Separation Systems for Commercial Biotechnology ... Trends, and Forecast 2015 - 2023", the separation ... US$ 10,665.5 Mn in 2014 and is projected ... 2015 to 2023 to reach US$ 19,227.8 Mn ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Intelligent Implant ... by the FDA via 510(k) for sale in the United States. These components ... posterior thoraco-lumbar fusions. With one-level sales beginning in October of 2015, the company ...
Breaking Biology Technology:
(Date:3/14/2016)... Allemagne, March 14, 2016 ... - --> - Renvoi : image disponible ... --> --> DERMALOG, ... fournit de nouveaux lecteurs d,empreintes digitales pour l,enregistrement ... DERMALOG sera utilisé pour produire des cartes d,identité ...
(Date:3/10/2016)... 10, 2016   Unisys Corporation (NYSE: UIS ... (CBP) is testing its biometric identity solution at the ... to help identify certain non-U.S. citizens leaving the country. ... designed to help determine the efficiency and accuracy of using ... and will run until May 2016. --> ...
(Date:3/8/2016)... March 8, 2016   Valencell , the ... announced it has secured $11M in Series D ... a new venture fund being launched by UAE-based ... from existing investors TDF Ventures and WSJ Joshua ... continue its triple-digit growth and accelerate its pioneering ...
Breaking Biology News(10 mins):